Lee, Chung-Han
Motzer, Robert J.
Glen, Hilary
Michaelson, M. D.
Larkin, James
Minoshima, Yukinori
Kanekiyo, Michio
Ikezawa, Hiroki
Sachdev, Pallavi
Dutcus, Corina E.
Funahashi, Yasuhiro
Voss, Martin H. http://orcid.org/0000-0003-0551-5807
Funding for this research was provided by:
This study was supported by Eisai, Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
This study was supported by Eisai, Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
This study was supported by Eisai, Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
This study was supported by Eisai, Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
This study was supported by Eisai, Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
This study was supported by Eisai, Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
This study was supported by Eisai, Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
This study was supported by Eisai, Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
This study was supported by Eisai, Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
This study was supported by Eisai, Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
Article History
Received: 24 January 2020
Revised: 2 July 2020
Accepted: 27 August 2020
First Online: 7 October 2020
Ethics approval and consent to participate
: This was an exploratory post hoc analysis; however, the source study followed the International Conference on Harmonization Good Clinical Practice guidelines (as required by the principles of the World Medical Association Declaration of Helsinki) and local regulations. The source study was approved by the respective institutional review board or independent ethics committee at each participating study centre; a listing of the institutional review boards and independent ethics committees is provided in Supplemental Table InternalRef removed. All patients provided written informed consent before enrolling.
: The data will not be available for sharing at this time as the data are commercially confidential. However, Eisai will consider written requests to share the data on a case-by-case basis.
: C.-H.L.: consulting or advisory role: Amgen, Bristol-Myers Squibb, Exelixis, Eisai; research funding: Bristol-Myers Squibb, Calithera, Eisai, Exelixis, Pfizer. R.J.M.: Consulting or advisory role: Pfizer, Eisai, Exelixis, Merck, Incyte, Novartis; research funding: Pfizer, Eisai, Exelixis, Genentech/Roche, Novartis, Bristol-Myers Squibb. H.G.: Advisory board or speaker fees: Astellas, Janssen, Eisai, Bayer, Merck, Ipsen; research funding: Eisai. M.D.M.: consulting or advisory role: Exelixis, Novartis, Pfizer; research funding: Bristol-Myers Squibb, Eisai; Exelixis, Merck, Pfizer. J.L.: Research funding: Pfizer (Inst), Novartis (Inst), Bristol-Myers Squibb, Merck Sharp & Dohme; personal fees: Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, Novartis, GlaxoSmithKline, Genentech, Eisai. J.L. is an editorial board member of the <i>British Journal of Cancer</i>. Y.M.: Employee of Eisai Co., Ltd. M.K.: Employee of Eisai Inc. H.I.: Employee of Eisai Co., Ltd. P.S.: Employee of Eisai Inc. C.E.D.: Employee of Eisai Inc. Y.F.: Employee of Eisai Co., Ltd. M.H.V.: consulting or advisory role: Alexion Pharmaceuticals, Calithera Biosciences, Exelixis, GlaxoSmithKline, Natera, Novartis, Pfizer; research funding: Bristol-Myers Squibb, Genentech/Roche, Pfizer; personal fees: Novartis, Takeda; travel fees: Novartis, Takeda, Eisai, AstraZeneca; honoraria: Novartis.
: This study was supported by Eisai, Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Medical writing support was funded by Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.